ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
FOXK2/SH2D3A axis recruits EGFR to drive papillary thyroid cancer progression and confers sensitivity to EGFR inhibition.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Papillary thyroid carcinoma (PTC) is the most prevalent malignant tumor of the endocrine system, yet the specific role of Forkhead box protein K2 (FOXK2) in its progression remains incompletely elucidated. Analyses based on public databases and 31 pairs of matched clinical specimens revealed that both FOXK2 and SH2D3A were significantly upregulated in PTC tissues and cell lines, with their expression levels showing a strong positive correlation. Functional experiments indicated that knockdown of FOXK2 or SH2D3A markedly inhibited PTC cell proliferation, invasion, and migration while reducing the phosphorylation of p38, ERK, and AKT. In FOXK2-knockdown cells, SH2D3A overexpression partially restored these oncogenic phenotypes and the activation of downstream signaling, a result further validated in nude mouse xenograft models. Mechanistically, FOXK2 was found to enhance SH2D3A transcription by directly binding to its promoter region. Co-immunoprecipitation assays further confirmed that SH2D3A directly interacts with the epidermal growth factor receptor (EGFR). Importantly, pharmacological inhibition of EGFR with Gefitinib effectively suppressed the activation of EGFR and ERK, thereby attenuating the oncogenic activity of the FOXK2/SH2D3A axis. Collectively, this study identifies a novel FOXK2/SH2D3A/EGFR signaling axis that contributes to PTC progression and may represent a potential therapeutic vulnerability in aggressive papillary thyroid cancer.
Indexed as
Identifiers
41984197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.